Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials

详细信息    查看全文

• 作者：Soichi Sakai ; Bachelor of Pharmacy¹ ; ^{so-sakai@so.taisho.co.jp" class="auth_mail" title="E-mail the corresponding author} ; Kohei Kaku ; MD ; PhD² ; Yutaka Seino ; MD ; PhD³ ; Nobuya Inagaki ; MD ; PhD⁴ ; Masakazu Haneda ; MD ; PhD⁵ ; Takashi Sasaki ; MD ; PhD⁶ ; Atsushi Fukatsu ; MD ; PhD⁷ ; Haruka Kakiuchi ; Master of Pharmacy¹ ; Yoshishige Samukawa ; Bachelor of Pharmacy¹
• 关键词：body mass index ; Japanese ; luseogliflozin ; obesity ; sodium-glucose cotransporter-2 ; type 2 diabetes mellitus
• 刊名：Clinical Therapeutics
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：38
• 期：4
• 页码：843-862.e9
• 全文大小：1402 K

文摘

Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, may be beneficial in obese diabetic patients based on its potential to decrease blood glucose and body weight, but there is limited proof. This analysis aimed to investigate the efficacy and safety of luseogliflozin in patients with varying levels of obesity.

Methods

A pooled analysis of four 52-week Phase III trials of luseogliflozin 2.5 mg daily (or up to 5 mg daily) in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index (BMI) was conducted. Efficacy end points included changes in glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight.

Findings

In total, 1031 patients were included and stratified into 5 BMI (kg/m²) groups: low-to-medium (<22.5, n = 222); medium (≥22.5 to <25, n = 270); high-level 1 (≥25 to <27.5, n = 262); high-level 2 (≥27.5 to <30, n = 142); and very-high (≥30, n = 135). HbA1c decreased significantly compared with baseline until week 52 in all groups, and a similar trend was observed with FPG and body weight. The reduction in glycemic parameters tended to be slightly smaller in patients with BMI <22.5 kg/m², and the reduction in body weight tended to be greater in patients with higher BMI, especially those with BMI ≥30 kg/m². Levels of fasting insulin, C-peptide immunoreactivity, triglyceride, blood pressure, aspartate aminotransferase, alanine aminotransferase, and uric acid decreased significantly at week 52 in all groups (except for aspartate aminotransferase in patients with BMI <22.5 kg/m²). Levels of these parameters tended to be higher at baseline and these enhanced levels resulted in a greater decrease in patients with higher BMI. In safety, the incidence of adverse events was similar between groups, and most of them were mild in severity.

Implications

HbA1c and body weight decreased significantly in all groups. Decrease in glycemic parameters tended to be smaller in patients with BMI <22.5 kg/m², while that of body weight was larger in patients with higher BMI. Furthermore, luseogliflozin was especially beneficial in patients with higher BMI in terms of metabolic abnormalities, including insulin secretion and hypertension. Luseogliflozin exhibited a favorable and similar safety profile over 52 weeks in all groups. This agent can be an effective and well-tolerated therapeutic option in patients with a wide range of BMI levels, and it may be more beneficial in patients with higher BMI.